Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735212 | 0.87 | KAT2B (0.38) | HRH3KDM4E | |
| SCHEMBL6733915 | 0.85 | HRH3 (0.40) | HRH3KDM4ETDP1 | |
| SCHEMBL7662241 | 0.83 | HRH3 (0.42) | HRH3KDM4EALDH1A1CYP3A4RECQL | |
| SCHEMBL7657040 | 0.79 | HRH3 (0.39) | HRH3 | |
| SCHEMBL6734314 | 0.75 | HRH3 (0.44) | HRH3KDM4ETDP1S1PR1 | |
| SCHEMBL6737938 | 0.75 | HRH3 (0.35) | HRH3KDM4EALDH1A1CYP3A4RECQL | |
| SCHEMBL6739873 | 0.74 | HRH3 (0.35) | HRH3KDM4EALDH1A1CYP3A4RECQL | |
| SCHEMBL6736330 | 0.74 | HRH3 (0.43) | HRH3KDM4EALDH1A1 | |
| SCHEMBL6732800 | 0.72 | HDAC3 (0.37) | HRH3KDM4EALDH1A1 | |
| SCHEMBL6735891 | 0.72 | HRH3 (0.42) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885KDM4E 4423/4885ALDH1A1 569/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885KDM4E 4423/4885ALDH1A1 569/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885KDM4E 4423/4885ALDH1A1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.